Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?
Executive Summary
Alnylam’s stock fell more than 40% in after-hours trading following the decision to end development of revusiran based on an imbalance of deaths in the Phase III ENDEAVOR clinical trial, but executives see no read-through to the rest of the company’s RNAi platform.
You may also be interested in...
Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade
Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Despite its stock price falling 48% 24 hours after the shuttering of lead candidate revusiran, Alnylam is encouraged by analyst reports indicating the failure does not read through to its overall pipeline. The biotech reaffirmed its timeline for its second Phase III candidate patisiran.
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Fitusiran's mechanism of reducing antithrombin levels could apply to all hemophilia patients, as well as those with other rare bleeding disorders. Reducing antithrombin increases thrombin levels and helps to increase normal clotting.
Need a specific report? 1000+ reports available
Buy Reports